Can a $50 billion valuation finally solve human disease? Sir Demis Hassabis is in talks to raise a monumental new round for Isomorphic Labs—taking AI-driven drug discovery from computer screens to human trials.
The Rise of Isomorphic Labs.
Founded in November 2021 as an Alphabet subsidiary spun out of Google DeepMind, Isomorphic Labs was created around an ambitious premise: leverage advanced computational models to revolutionize biotechnology and ultimately solve all human disease. Led by founder and CEO Sir Demis Hassabis—co-founder of DeepMind and co-recipient of the 2024 Nobel Prize in Chemistry—the London-headquartered firm has rapidly evolved from an ambitious research endeavor into an ultra-capitalized biotechnology power player.
Now, as Sir Demis Hassabis holds talks to raise new funding at a $50 billion valuation, Isomorphic stands on the precipice of its most critical evolution yet: proving whether its revolutionary computational designs can successfully translate into real-world human therapeutics.
Key Operational Pillars.
1. Breakthrough Technology Platform.
At the core of the company is the Isomorphic Labs.
Drug Design Engine (IsoDDE). Performance benchmarks highlight significant advancements over baseline AI models:
* Protein-Ligand Precision: IsoDDE more than doubles the accuracy of AlphaFold 3 on the most complex protein-ligand systems.
* Biologics & Affinity: Demonstrates 2.3 times higher high-fidelity prediction accuracy for antibody-antigen interactions and surpasses traditional physics-based methods (e.g., free-energy perturbation) in binding-affinity predictions without requiring experimental crystal structures.
* Target Identification: Identifies novel ligandable pockets directly from amino acid sequences, opening up previously “undruggable” targets.
2. Strategic Dual-Track Business Model.
Isomorphic operates across two distinct tracks designed to balance immediate revenue with long-term commercial upside:
* Big-Pharma Collaborations: Formed high-value partnerships with Eli Lilly ($45M upfront; up to $1.7B in potential milestones), Novartis ($37.5M upfront; up to $1.2B in potential milestones, expanded in 2025), and Johnson & Johnson (spanning small molecules, biologics, peptides, and molecular glues).
* Wholly Owned Pipeline: Develops an internal pipeline targeting structurally complex protein targets in oncology and immune-mediated disorders.
3. Capitalization & Global Scale.
* Unprecedented Capitalization: Raised $600M in a March 2025 Series A led by Thrive Capital, followed by a landmark $2.1B Series B in May 2026 (the largest financing round in AI-driven drug discovery history). Total outside capital raised stands at $2.7B.
* Global Footprint: Headquartered in London with a major research office in Lausanne, Switzerland, with capital earmarked for aggressive international scaling.
* Key Leadership: Strengthened its executive team by naming founding member Max Jaderberg as President.
Critical near-term catalysts & key risks.
Category Details.
First Clinical Validation Targets filing its first Investigational New Drug (IND) application and initiating first-in-human testing by the end of 2026.
Pharma Milestones Near-term financial upside hinges on reaching performance and clinical progress milestones with Lilly, Novartis, and J&J.
Translational Risk No Isomorphic-designed molecule has been dosed in humans yet. Assets still face standard preclinical risks, including unpredicted toxicity or poor pharmacokinetics.
Model Verification Platform performance numbers (IsoDDE) are company-reported benchmarks that have yet to be independently validated in peer-reviewed clinical settings.
#ArtificialIntelligence #isomorphiclabs #DemisHassabis #DrugDiscovery #Biotechnology
An Alphabet subsidiary spun out of Google DeepMind, Isomorphic Labs designs drugs computationally, with oncology and immunology programs in IND-enabling studies and first-in-human testing targeted for the end of 2026.
Isomorphic Labs is an Alphabet subsidiary, spun out of Google DeepMind, that designs drug molecules computationally. Its own programs target oncology and immune-mediated disease.
The business runs on two tracks. Research collaborations with Eli Lilly, Novartis and Johnson & Johnson bring in upfront payments, research funding and milestone potential. A wholly owned pipeline moves separately toward the clinic.